164 related articles for article (PubMed ID: 17159496)
1. Sulfoglycolipids as candidate antiangiogenic radiosensitizers.
Miura M; Sakimoto I; Ohta K; Sugawara F; Sakaguchi K
Anticancer Drugs; 2007 Jan; 18(1):1-5. PubMed ID: 17159496
[TBL] [Abstract][Full Text] [Related]
2. The interaction of radiation therapy and antiangiogenic therapy.
O'Reilly MS
Cancer J; 2008; 14(4):207-13. PubMed ID: 18677126
[TBL] [Abstract][Full Text] [Related]
3. Radiation combined with antiangiogenic and antivascular agents.
O'Reilly MS
Semin Radiat Oncol; 2006 Jan; 16(1):45-50. PubMed ID: 16378906
[TBL] [Abstract][Full Text] [Related]
4. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
5. Alpha-sulfoquinovosylmonoacylglycerol is a novel potent radiosensitizer targeting tumor angiogenesis.
Sakimoto I; Ohta K; Yamazaki T; Ohtani S; Sahara H; Sugawara F; Sakaguchi K; Miura M
Cancer Res; 2006 Feb; 66(4):2287-95. PubMed ID: 16489033
[TBL] [Abstract][Full Text] [Related]
6. [Angiogenesis: all a radiation oncologist should know].
Mazeron R; Bourhis J; Deutsch E
Cancer Radiother; 2008 Jan; 12(1):50-60. PubMed ID: 18243753
[TBL] [Abstract][Full Text] [Related]
7. The combination of antiangiogenic therapy with other modalities.
O'Reilly MS
Cancer J; 2002; 8 Suppl 1():S89-99. PubMed ID: 12075706
[TBL] [Abstract][Full Text] [Related]
8. Angiogenic tumor markers, antiangiogenic agents and radiation therapy.
Chan LW; Camphausen K
Expert Rev Anticancer Ther; 2003 Jun; 3(3):357-66. PubMed ID: 12820778
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy.
Ansiaux R; Baudelet C; Jordan BF; Crokart N; Martinive P; DeWever J; Grégoire V; Feron O; Gallez B
Cancer Res; 2006 Oct; 66(19):9698-704. PubMed ID: 17018628
[TBL] [Abstract][Full Text] [Related]
10. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Launay-Vacher V; Deray G
Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.
Manegold PC; Paringer C; Kulka U; Krimmel K; Eichhorn ME; Wilkowski R; Jauch KW; Guba M; Bruns CJ
Clin Cancer Res; 2008 Feb; 14(3):892-900. PubMed ID: 18245553
[TBL] [Abstract][Full Text] [Related]
12. Endostatin: the logic of antiangiogenic therapy.
Abdollahi A; Hlatky L; Huber PE
Drug Resist Updat; 2005; 8(1-2):59-74. PubMed ID: 15939343
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic therapy and surgical practice.
John AR; Bramhall SR; Eggo MC
Br J Surg; 2008 Mar; 95(3):281-93. PubMed ID: 18278790
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapy for cancer: an update.
Shojaei F; Ferrara N
Cancer J; 2007; 13(6):345-8. PubMed ID: 18032969
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenics and radiotherapy.
Shannon AM; Williams KJ
J Pharm Pharmacol; 2008 Aug; 60(8):1029-36. PubMed ID: 18644195
[TBL] [Abstract][Full Text] [Related]
16. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.
van Heeckeren WJ; Sanborn SL; Narayan A; Cooney MM; McCrae KR; Schmaier AH; Remick SC
Curr Opin Hematol; 2007 Sep; 14(5):468-80. PubMed ID: 17934353
[TBL] [Abstract][Full Text] [Related]
17. Modulating the tumor microenvironment to improve radiotherapy.
Maity A
Retina; 2009 Jun; 29(6 Suppl):S32-3. PubMed ID: 19553796
[TBL] [Abstract][Full Text] [Related]
18. The potential of antiangiogenic therapy in non-small cell lung cancer.
Giaccone G
Clin Cancer Res; 2007 Apr; 13(7):1961-70. PubMed ID: 17404076
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
Cao Y
Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises.
Van Langendonckt A; Donnez J; Defrère S; Dunselman GA; Groothuis PG
Mol Hum Reprod; 2008 May; 14(5):259-68. PubMed ID: 18430758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
